萬泰生物(603392.SH):萬泰凱瑞擬13.36億元投建廈門萬泰診斷基地建設項目
格隆匯7月6日丨萬泰生物(603392.SH)公佈,公司全資子公司廈門萬泰凱瑞生物技術有限公司(“萬泰凱瑞”)擬投資建設和實施“廈門萬泰診斷基地建設項目”(簡稱“診斷基地項目”)。根據可行性研究報吿測算,項目預計總投資為13.36億元(包含土地購置3870.00萬元),其中:建設投資11.159億元,建設期利息5145.00萬元,鋪底流動資金1.6859億元,項目建設週期計劃3年,即2021-2023年。
項目建成後,將形成5億人份/年的體外診斷試劑生產能力以及9000台套/年的檢驗設備的生產能力。
此次診斷基地建設項目的落地,配套研發、生產等相關設備和人員的加大投入,一方面,將進一步提升新產品的開發能力,完善公司產品線,加快在化學發光這一診斷細分領域的佈局;另一方面,將大幅提升公司在大、小型體外診斷設備、以及體外診斷試劑上的生產能力與生產效率,進一步加快新產品轉產速度,從而鞏固和增強公司在體外診斷領域的整體競爭力和市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.